Here, our results suggest that topical SOCS1-KIR administration could ameliorate uveitis pathology on two distinct levels: (1) through direct inhibition of immunopathology mediated by uveitogenic T lymphocytes and (2) by protecting resident ocular cells from apoptosis during chronic intraocular inflammatory diseases. Here, SOCS1 is linked to uveitis.